Rank #1911EOLS

Evolus, Inc. Common Stock

$4.42

1.84% (Daily)

Market Cap

$286.50M

Revenue

$285.82M

Rank by MCap

#1911

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. David Moatazedi

Headquarters

Newport Beach, CA

Employees

329

About Evolus, Inc. Common Stock

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.